Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy
Stanic, Karmen, Vrankar, Martina, But-Hadzic, Jasna
Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy
Vrankar, Martina, Stanic, Karmen
Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe
Zemanova, Milada, Jakopovic, Marko, Stanic, Karmen, Łazar-Poniatowska, Małgorzata, Vrankar, Martina, Rusu, Petronela, Ciuleanu, Tudor, Radosavljevic, Davorin, Bogos, Krisztina, Nawrocki, Sergiusz
Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia
Stanic, Karmen, But-Hadzic, Jasna, Zagar, Jan, Vrankar, Martina
Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
Vrankar, Martina, Stanic, Karmen, Jelercic, Stasa, Ciric, Eva, Vodusek, Ana Lina, But-Hadzic, Jasna
[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab
Valentinuzzi, Damijan, Vrankar, Martina, Boc, Nina, Ahac, Valentina, Zupancic, Ziga, Unk, Mojca, Skalic, Katja, Zagar, Ivana, Studen, Andrej, Simoncic, Urban, Eickhoff, Jens, Jeraj, Robert
Various clinical presentations of uveitis associated with durvalumab treatment
Vrabic, Nika, Fakin, Ana, Mekjavic, Polona Jaki, Janzic, Urska, Vrankar, Martina, Valentincic, Natasa Vidovic
Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients
Stanic, Karmen, Turnsek, Nina, Vrankar, Martina
Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
Zwitter, Matjaz, Stanic, Karmen, Rajer, Mirjana, Kern, Izidor, Vrankar, Martina, Edelbaher, Natalija, Kovac, Viljem
Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial
Vrankar, Martina, Zwitter, Matjaz, Bavcar, Tanja, Milic, Ana, Kovac, Viljem
Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy
Vrankar, Martina, Unk, Mojca